Trials / Completed
CompletedNCT00850044
Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
A Double-Blind, Randomized, Placebo-Controlled, Nonfasting Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Doses of ABT-450 With and Without Ritonavir
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-450 | capsules,QD, one dose, see Arm Descriptions for more information |
| DRUG | ritonavir | capsules, QD, one dose, escalating doses, see Arm Descriptions for more information |
| DRUG | placebo for ABT-450 | capsules, QD, one dose |
| DRUG | Placebo for ritonavir | capsules, QD, one dose |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-07-01
- First posted
- 2009-02-24
- Last updated
- 2017-11-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00850044. Inclusion in this directory is not an endorsement.